KI
HAE icon

Kalmar Investments’s Haemonetics HAE Stock Holding History

Kalmar Investments’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-992,090
Closed -$41.8M – 159
2013
Q4 		$41.8M Sell
992,090
-2,660
-0.3% -$109K 0.7% 57
2013
Q3 		$39.7M Buy
994,750
+944,750
+1,890% +$39.6M 0.7% 57
2013
Q2 		$2.07M Buy
+50,000
New +$2.02M 0.04% 155

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Kalmar Investments's HAE Position: Q1 2014 in Review

Kalmar Investments sold out of Haemonetics (HAE) in Q1 2014, closing a stake of 992,090 shares — an estimated $41.8M sold.

Kalmar Investments first reported a position in HAE in Q2 2013 and held it in 3 quarters. The position peaked at $41.8M in Q4 2013. 192 funds tracked by Wall St. Rank hold HAE as of Q1 2014.

  • Kalmar Investments reported no remaining Haemonetics position as of Q1 2014 after selling out during the quarter.
  • Kalmar Investments sold 992,090 Haemonetics shares in Q1 2014, an estimated $41.8M.
  • Kalmar Investments first reported a position in Haemonetics in Q2 2013 and held it in 3 quarters.
  • Kalmar Investments's Haemonetics position peaked at $41.8M in Q4 2013.
  • 192 funds tracked by Wall St. Rank held Haemonetics as of Q1 2014.

Based on Kalmar Investments's 13F filing for Q1 2014, filed 23 Apr 2014.